The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are ...

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam ...

"This launch represents a major expansion of our professional learning portfolio, enabling us to provide even more impactful ...

At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in ...

KCNK13 was identified by Cerevance's proprietary NETSseq platform. About Solengepras (formerly CVN424) Solengepras is ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to improve motor and non-motor functions in participants with early PD.

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo.

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

Prazer Therapeutics raises $20M Series B with JJDC's first South Korean investment; Carisma cuts to 6 staff; Cerevance's Parkinson's trial fails; FDA updates for Oncopeptides, Bavarian Nordic ...